Advanced Filters
noise

Peking, China Clinical Trials

A listing of Peking, China clinical trials actively recruiting patients volunteers.

Found 2,907 clinical trials
K Kan Gong, PhD

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.

18 - 80 years of age All Phase 1
T TingBo Liang, MD, PHD

A Phase I/IIa,Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YOLT-201 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM).

18 - 80 years of age All Phase 1/2

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy …

18 years of age All Phase 1/2
S Shuai Sun

Online Adaptive Radiotherapy for Cervical Cancer

This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.

18 - 80 years of age Female Phase 2
E Ethics Committee

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.

14 - 75 years of age All Phase 1/2
Q Qingqing Cai, MD

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.

18 years of age All Phase 2
H Haitao Zhao, MD

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma. The main questions it aims to answer are: Objective response rate (ORR) for evaluation Disease Control Rate (DCR); Duration of relief (DoR); Progression free …

18 - 75 years of age All Phase 1
F Fang Cheng, M.D.

Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis

This study will evaluate the efficacy and safety of Jiuweihuaban Pill in the treatment of moderate to severe plaque psoriasis(syndrome of blood-heat ).

18 - 65 years of age All Phase 2
J Jun Guo, Director

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.

18 - 80 years of age All Phase 1/2
B Binghe Xu

Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

This study plans to include approximately 60-100 patients with advanced solid tumors who have progressed on clinical trial drugs. It will use an open-label, single-arm, multi-cohort umbrella design. In the first phase, patients who have progressed during treatment with novel tumor immunotherapy drugs will initially be targeted, combining or sequencing …

18 years of age All Phase 1/2

Simplify language using AI